Metabolism and disposition of imatinib mesylate in healthy volunteers
…, F Waldmeier, M Zollinger, C Sayer, P Zbinden… - Drug metabolism and …, 2005 - ASPET
Imatinib mesylate (GLEEVEC, GLIVEC, formerly STI571) has demonstrated unprecedented
efficacy as first-line therapy for treatment for all phases of chronic myelogenous leukemia …
efficacy as first-line therapy for treatment for all phases of chronic myelogenous leukemia …
Chimeric peptidomimetic antibiotics against Gram-negative bacteria
…, R Jaisson, V Rithié, G Upert, A Lederer, P Zbinden… - Nature, 2019 - nature.com
There is an urgent need for new antibiotics against Gram-negative pathogens that are
resistant to carbapenem and third-generation cephalosporins, against which antibiotics of last …
resistant to carbapenem and third-generation cephalosporins, against which antibiotics of last …
Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae
…, S Hell, S Gable, V Rithié, S Dillinger, P Zbinden… - Science …, 2023 - science.org
The rise of antimicrobial resistance poses a substantial threat to our health system, and,
hence, development of drugs against novel targets is urgently needed. The natural peptide …
hence, development of drugs against novel targets is urgently needed. The natural peptide …
Use of FLIPR membrane potential dyes for validation of high-throughput screening with the FLIPR and µARCS technologies: identification of ion channel modulators …
…, SP Parel, A Bergner, P Zbinden… - Journal of …, 2008 - journals.sagepub.com
Fluorometric imaging plate reader (FLIPR) membrane potential dyes (FMP-Red-Dye and
FMP-Blue-Dye) were evaluated for the detection of compounds acting either as positive …
FMP-Blue-Dye) were evaluated for the detection of compounds acting either as positive …
Pseudoreceptor modeling: The construction of three-dimensional receptor surrogates
A Vedani, P Zbinden, JP Snyder… - Journal of the American …, 1995 - ACS Publications
Pseudoreceptor modeling allows the construction of a receptor surrogate for a structurally
uncharacterized bioregulator (an enzyme or receptor) based on the structures of known ligand …
uncharacterized bioregulator (an enzyme or receptor) based on the structures of known ligand …
Pseudo-receptor modeling: a new concept for the three-dimensional construction of receptor binding sites
A Vedani, P Zbinden, JP Snyder - Journal of receptor research, 1993 - Taylor & Francis
Molecular design of small molecules intended to target a macromolecule generally utilizes
one of two computational approaches: «receptor fitting» or «receptor mapping». A …
one of two computational approaches: «receptor fitting» or «receptor mapping». A …
PrGen: Pseudoreceptor modeling using receptor‐mediated ligand alignment and pharmacophore equilibration
P Zbinden, M Dobler, G Folkers… - Quantitative Structure …, 1998 - Wiley Online Library
Based on the structures of known ligand molecules, a pseudoreceptor modeling concept
developed at our laboratory allows the construction of a peptidic binding‐site model for a …
developed at our laboratory allows the construction of a peptidic binding‐site model for a …
Quasi-atomistic receptor surface models: A bridge between 3-D QSAR and receptor modeling
A Vedani, M Dobler, P Zbinden - Journal of the American …, 1998 - ACS Publications
A “quasi-atomistic receptor model” refers to a three-dimensional receptor surface, populated
with atomistic properties (hydrogen bonds, salt bridges, hydrophobic particles, and solvent) …
with atomistic properties (hydrogen bonds, salt bridges, hydrophobic particles, and solvent) …
The Integrated Use of Alternative Approaches for Predicting Toxic Hazard: The Report and Recommendations of ECVAM Workshop 8,
…, FA Rutten, HJM Verhaar, P Zbinden - Alternatives to …, 1995 - journals.sagepub.com
This is the report of the eighth of a series of workshops organised by the European Centre
for the Validation of Alternative Methods (ECV AM). ECV AM's main goal, as defined in 1993 …
for the Validation of Alternative Methods (ECV AM). ECV AM's main goal, as defined in 1993 …
The evolution of microarrayed compound screening
M Hoever, P Zbinden - Drug Discovery Today, 2004 - Elsevier
This review describes recent developments in the evolutionary process of microarrayed
compound screening (μARCS™) to become a robust and efficient ultra-high-throughput …
compound screening (μARCS™) to become a robust and efficient ultra-high-throughput …